- Home
- EOD vs CKPT Comparison
EOD vs CKPT Comparison
Compare EOD & CKPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EOD
- CKPT
- Stock Information
- Founded
- EOD 2007
- CKPT 2014
- Country
- EOD United States
- CKPT United States
- Employees
- EOD N/A
- CKPT N/A
- Industry
- EOD Investment Managers
- CKPT Biotechnology: Pharmaceutical Preparations
- Sector
- EOD Finance
- CKPT Health Care
- Exchange
- EOD Nasdaq
- CKPT Nasdaq
- Market Cap
- EOD 213.8M
- CKPT 172.4M
- IPO Year
- EOD N/A
- CKPT 2017
- Fundamental
- Price
- EOD $5.00
- CKPT $4.04
- Analyst Decision
- EOD
- CKPT Buy
- Analyst Count
- EOD 0
- CKPT 3
- Target Price
- EOD N/A
- CKPT $4.33
- AVG Volume (30 Days)
- EOD 118.1K
- CKPT 5.7M
- Earning Date
- EOD 01-01-0001
- CKPT 03-28-2025
- Dividend Yield
- EOD 9.28%
- CKPT N/A
- EPS Growth
- EOD N/A
- CKPT N/A
- EPS
- EOD N/A
- CKPT N/A
- Revenue
- EOD N/A
- CKPT $41,000.00
- Revenue This Year
- EOD N/A
- CKPT $102,182.93
- Revenue Next Year
- EOD N/A
- CKPT $351.71
- P/E Ratio
- EOD N/A
- CKPT N/A
- Revenue Growth
- EOD N/A
- CKPT N/A
- 52 Week Low
- EOD $3.73
- CKPT $1.38
- 52 Week High
- EOD $4.71
- CKPT $4.50
- Technical
- Relative Strength Index (RSI)
- EOD 48.01
- CKPT 65.90
- Support Level
- EOD $4.87
- CKPT $4.01
- Resistance Level
- EOD $5.09
- CKPT $4.06
- Average True Range (ATR)
- EOD 0.06
- CKPT 0.03
- MACD
- EOD -0.00
- CKPT -0.01
- Stochastic Oscillator
- EOD 59.09
- CKPT 70.00
About EOD Allspring Global Dividend Opportunity Fund of Beneficial Interest
Allspring Global Dividend Opportunity Fund is a diversified closed-end management investment company. Its primary investment objective is to seek a high level of current income. The fund's secondary objective is the long-term growth of capital. The fund allocates its assets between two separate investment strategies or sleeves. Under normal market conditions, the fund allocates approximately 80% of its total assets to an equity sleeve comprised of common stocks.
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.